Dr. Swathi Merugu | Immunoinformatics | Best Researcher Award
Dr. Swathi Merugu | Senior Research Scientist | Memorial Sloan Kettering Cancer Centre | United States
Academic Background
Dr. Swathi Merugu holds a Ph.D. in Cancer Research from Newcastle University, U.K., focusing on clinical medicine and pediatric oncology. She completed her postdoctoral fellowship in Translational Cancer Research with a specialization in Precision Medicine at Memorial Sloan Kettering Cancer Center. Her foundational training includes a Master’s in Pharmacy in Pharmacology and a Bachelor of Pharmacy, both from Kakatiya University, India. Throughout her academic journey, she has authored multiple scientific documents and accumulated significant citations reflecting her impactful research contributions. Her Scopus profile shows 88 citations across 56 documents with an h-index of 4, while Google Scholar lists 382 citations from 259 documents, highlighting an h-index of 10 and an i10-index of 10, underscoring her scholarly influence in the field.
Research Focus
Dr. Merugu’s research is centered on precision oncology and immunotherapy, with particular expertise in pediatric cancers and hematologic malignancies. Her work emphasizes the development of non-invasive biomarker assays and immune-monitoring strategies to enhance patient-centered clinical trials and optimize therapeutic interventions.
Work Experience
Dr. Merugu currently serves as a Senior Research Scientist at Memorial Sloan Kettering Cancer Center, leading projects in immune-monitoring assays and biomarker discovery, fostering collaboration between clinical researchers and laboratory scientists. Her postdoctoral work at the same institution advanced the understanding of epichaperome inhibition in acute myeloid leukemia, translating preclinical findings into clinical applications. She has also held a position as Assistant Professor at Kakatiya University, mentoring graduate students in oncology and pharmacology, and guiding early-stage research projects.
Key Contributions
Dr. Merugu has pioneered the development of flow cytometry-based assays to detect targetable cancer populations, significantly contributing to personalized medicine. She led groundbreaking studies utilizing circulating tumor cells as predictive biomarkers in neuroblastoma, influencing early-phase clinical trial protocols internationally. Her research in acute myeloid leukemia demonstrated the immunomodulatory effects of epichaperome inhibition, opening new avenues for targeted precision therapies.
Awards & Recognition
She has received recognition for her outstanding presentations and research achievements, including a prestigious oral presentation award at Memorial Sloan Kettering Cancer Center and a scholarship for her doctoral studies at Newcastle University.
Professional Roles & Memberships
Dr. Merugu is an accomplished research leader and mentor, known for her ability to manage cross-functional clinical research teams and coordinate complex trials. She collaborates with clinicians, regulatory bodies, and laboratory scientists to ensure high-quality translational research while fostering scientific mentorship and professional development for junior researchers.
Profile
Scopus | Google Scholar | Research Gate | LinkedIn
Featured Publications
Merugu, S., Chen, L., Gavens, E., Gabra, H., Brougham, M., Makin, G., Ng, A. Detection of circulating and disseminated neuroblastoma cells using the ImageStream flow cytometer for use as predictive and pharmacodynamic biomarkers. Clinical Cancer Research, 26, 122-134.
Merugu, S., Sharma, S., Kaner, J., Digwal, C., Sugita, M., Joshi, S., Taldone, T. Chemical probes and methods for single-cell detection and quantification of epichaperomes in hematologic malignancies. Methods in Enzymology, 639, 289-311.
Rodina, A., Xu, C., Digwal, C., Joshi, S., Seela, A., Bay, S., Merugu, S. Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature Communications, 14, 3742.
Sugita, M., Wilkes, D.C., Bareja, R., Eng, K.W., Nataraj, S., Jimenez-Flores, R.A., Merugu, S. Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ Precision Oncology, 5, 44.
Joshi, S., Gomes, E.D.G., Wang, T., Corben, A., Taldone, T., Gandu, S., Merugu, S. Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. Communications Biology, 4, 1333.
Impact Statement / Vision
Dr. Merugu envisions advancing precision oncology by integrating biomarker discovery and immune-monitoring innovations into clinical practice. She is committed to translating cutting-edge research into therapies that improve patient outcomes while mentoring the next generation of clinical scientists.